Freenome's newly approved blood test offers clinicians an alternative screening option for average-risk adults aged 45 and ...

HealthDay News — The 2026 American Heart Association/American College of Cardiology/multisociety guideline on the management of dyslipidemia has increased the US population recommended for primary ...

Supported by four phase 3 clinical trials, Simtriyo offers a novel triple-reuptake inhibition mechanism for managing core ADHD symptoms across pediatric and adult populations.

Researchers found that the global morbidity gap increased from 8.8 to 10.7 years from 1990 to 2023, a 21.9% increase. HealthDay News — The global morbidity gap increased from 1990 to 2023, according ...

Emergency presentation (EP) for cancer diagnosis is common among older US adults and predicts persistently elevated mortality, according to a study published online July 14 in the Journal of the ...

The votes are nonbinding, but they amount to a rebuke of the FDA’s own scientists who said the drugs have not been studied enough to know whether they are safe or effective.

Cancer progression within 36 months of combination therapy identified patients with overall survival of less than 2 years.

In the RAS G12-mutated population, daraxonrasib significantly improved median OS (13.2 vs 6.6 months) and median PFS (7.3 vs 3.5 months) compared with chemotherapy. The Food and Drug Administration ...

Retatrutide 12mg achieved up to 22.6% (55.8 lbs) mean weight loss at week 80, alongside marked improvements in ...

In a scientific statement, the association states that consuming caffeinated coffee linked to reduced risks for type 2 diabetes, heart disease, stroke, heart failure.

Jideytro is FDA-approved for adult patients with locally advanced or metastatic ROS1-positive NSCLC who received prior ROS1 TKI therapy.